Clinical research

Pharmacodynamics of cisatracurium intravenously infused in infants and young children undergoing living donor liver transplantation

  • Wen YIN ,
  • Teng WANG ,
  • Yu-xi ZHOU ,
  • Yan-nan HANG ,
  • Da-xiang WEN
Expand
  • Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

Online published: 2021-06-29

Supported by

National Natural Science Foundation of China(81771236)

Abstract

Objective

·To observe pharmacodynamics of cisatracurium intravenously infused in infants and young children with end-stage liver disease during living donor liver transplantation.

Methods

·Sixteen patients of American Society of Anesthesiologists (ASA) physical status Ⅲ and Ⅳ, aged 6-24 months, with end-stage liver disease, undergoing liver transplantation were studied. Neuromuscular transmission was monitored by the responses of the adductor pollicis to train-of-four (TOF) stimulation of ulnar nerve, using the accelerography (TOF-Watch). Endotracheal intubation was performed after intravenous injection of 0.15 mg/kg cisatracurium, with T1 being the maximum inhibitory degree. After recovery of T1 to 3%, cisatracurium was infused at an initial rate of 2 μg/(kg·min). The infusion rate was adjusted to maintain a constant 90% to 95% neuromuscular paralysis until the end of the operation. The onset time, no reaction period of TOF, the dosage of cisatracurium given during paleo-phepatic phase, an-hepatic phase and neo-hepatic phase, the time to 25% recovery of T1, recovery index (25%?75%), and the time for the TOF ratio (TOFr) to reach 0.9 were recorded respectively.

Results

·The infusion rate was (1.37±0.46) μg/(kg·min). The average infusion rate of drugs in the three different periods showed a downward trend, but there was no statistical difference (P=0.110). The onset time of cisatracurium was (242.63±46.74) s. The no reaction period of TOF was (34.02±7.71) min. Following termination of the infusion, the time to 25% recovery of T1 was (12.80±3.49) min, and the recovery index (25%?75%) was (15.12±4.59) min. The time of TOFr=0.9 was (40.27±7.03) min.

Conclusion

·The pharmacodynamical characteristics of muscle relaxants should be fully understood during living donor liver transplantation in infants and young children with end-liver disease. When cisatracurium (0.15 mg/kg) is used for anesthesia induction, endotracheal intubation should be performed 4 min after administration. In the maintenance stage of anesthesia, the infusion dose requirement of cisatracurium is basically unchanged in the three different periods,and the infusion rate of 1.4 μg/(kg·min) can provide satisfactory muscle relaxation effect.

Cite this article

Wen YIN , Teng WANG , Yu-xi ZHOU , Yan-nan HANG , Da-xiang WEN . Pharmacodynamics of cisatracurium intravenously infused in infants and young children undergoing living donor liver transplantation[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(6) : 761 -763 . DOI: 10.3969/j.issn.1674-8115.2021.06.009

References

1 Rawal N, Yazigi N. Pediatric liver transplantation[J]. Pediatr Clin North Am, 2017, 64(3): 677-684.
2 Cammu G, Bossuyt G, De Baerdemaeker L, et al. Dose requirements and recovery profile of an infusion of cisatracurium during liver transplantation[J]. J Clin Anesth, 2002, 14(2):135-139.
3 De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation[J]. Br J Anaesth, 1996, 76(5): 624-628.
4 殷文, 闻大翔, 杭燕南. 婴幼儿活体肝移植术中罗库溴铵持续输注的药效学研究[J]. 上海交通大学学报(医学版), 2014, 34(9): 1381-1385.
5 ShangGuan W, Lian Q, Li J, et al. Clinical pharmacology of cisatracurium during nitrous oxide-propofol anesthesia in children[J]. J Clin Anesth, 2008, 20(6): 411-414.
6 Meakin GH, Meretoja OA, Perkins RJ, et al. Tracheal intubating conditions and pharmacodynamics following cisatracurium in infants and children undergoing halothane and thiopental-fentanyl anesthesia[J]. Paediatr Anaesth, 2007, 17(2):113-120.
7 温小林. 探讨不同剂量顺式阿曲库铵在小儿麻醉中对肌肉松弛的影响[J]. 中国医学前沿杂志(电子版), 2015, 7(1): 92-94.
8 周洁, 王祥瑞. 婴幼儿和成年患者活体肝移植术中顺阿曲库铵的药效学[J]. 中华麻醉学杂志, 2010(3): 262-265.
9 Guo J, Zhou X, Yuan X, et al. Age and the neuromuscular blockading effects of cisatracurium[J]. Int J Clin Exp Med, 2015, 8(9): 16664-16669.
10 Taivainen T, Meakin GH, Meretoja OA, et al. The safety and efficacy of cisatracurium 0.15 mg·kg-1 during nitrous oxide-opioid anaesthesia in infants and children[J]. Anaesthesia, 2000, 55(11):1047-1051.
11 Xiaobo F, Jianjuan K, Yanlin W. Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia[J]. Braz J Med Biol Res, 2012, 45(7): 676-680.
12 朱宇麟, 景桂霞, 赵鸽, 等. 顺苯磺酸阿曲库铵在肝移植患者应用中的肌松效果及安全性[J]. 广东医学, 2009, 30(4): 588-589.
13 Withington D, Ménard G, Varin F. Cisatracurium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children[J]. Paediatr Anaesth, 2011, 21(3): 341-346.
14 Guo J, Yuan X, Zhou X, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients undergoing surgery with two hemodilution methods[J]. J Clin Anesth, 2017, 38: 75-80.
Outlines

/